Kevin Tang - Mar 13, 2023 Form 4 Insider Report for Jounce Therapeutics, Inc. (JNCE)

Role
10%+ Owner
Signature
/s/ Kevin Tang
Stock symbol
JNCE
Transactions as of
Mar 13, 2023
Transactions value $
$85,958
Form type
4
Date filed
3/14/2023, 08:39 PM
Previous filing
Aug 24, 2022
Next filing
May 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNCE Common Stock Purchase $65.3K +65.7K +1.26% $0.99 5.28M Mar 13, 2023 By LP F1, F2
transaction JNCE Common Stock Purchase $20.7K +20.3K +0.38% $1.02 5.3M Mar 14, 2023 By LP F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 herein.
F2 The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
F3 The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.00 to $1.02.